1
|
Esteban J, Salar-Vidal L, Schmitt BH, Waggoner A, Laurent F, Abad L, Bauer TW, Mazariegos I, Balada-Llasat JM, Horn J, Wolk DM, Jefferis A, Hermans M, Verhoofstad I, Butler-Wu SM, Umali-Wilcox M, Murphy C, Cabrera B, Craft D, von Bredow B, Leber A, Everhart K, Dien Bard J, Flores II, Daly J, Barr R, Holmberg K, Graue C, Kensinger B. Multicenter evaluation of the BIOFIRE Joint Infection Panel for the detection of bacteria, yeast, and AMR genes in synovial fluid samples. J Clin Microbiol 2023; 61:e0035723. [PMID: 37877730 PMCID: PMC10662359 DOI: 10.1128/jcm.00357-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Accepted: 09/07/2023] [Indexed: 10/26/2023] Open
Abstract
The bioMérieux BIOFIRE Joint Infection (JI) Panel is a multiplex in vitro diagnostic test for the simultaneous and rapid (~1 h) detection of 39 potential pathogens and antimicrobial resistance (AMR) genes directly from synovial fluid (SF) samples. Thirty-one species or groups of microorganisms are included in the kit, as well as several AMR genes. This study, performed to evaluate the BIOFIRE JI Panel for regulatory clearance, provides data from a multicenter evaluation of 1,544 prospectively collected residual SF samples with performance compared to standard-of-care (SOC) culture for organisms or polymerase chain reaction (PCR) and sequencing for AMR genes. The BIOFIRE JI Panel demonstrated a sensitivity of 90.9% or greater for all but six organisms and a positive percent agreement (PPA) of 100% for all AMR genes. The BIOFIRE JI Panel demonstrated a specificity of 98.5% or greater for detection of all organisms and a negative percent agreement (NPA) of 95.7% or greater for all AMR genes. The BIOFIRE JI Panel provides an improvement over SOC culture, with a substantially shorter time to result for both organisms and AMR genes with excellent sensitivity/PPA and specificity/NPA, and is anticipated to provide timely and actionable diagnostic information for joint infections in a variety of clinical scenarios.
Collapse
Affiliation(s)
- Jaime Esteban
- IIS-Fundacion Jimenez Diaz, CIBERINFEC-CIBER de Enfermedades Infecciosas, Madrid, Spain
| | - Llanos Salar-Vidal
- IIS-Fundacion Jimenez Diaz, CIBERINFEC-CIBER de Enfermedades Infecciosas, Madrid, Spain
| | - Bryan H. Schmitt
- Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - Amy Waggoner
- Indiana University School of Medicine, Indianapolis, Indiana, USA
| | | | | | | | | | | | - Jared Horn
- The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | | | | | | | | | | | | | - Caitlin Murphy
- University of Nebraska Medical Center Omaha, Omaha, Nebraska, USA
| | - Barbara Cabrera
- University of Nebraska Medical Center Omaha, Omaha, Nebraska, USA
| | - David Craft
- The Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA
| | | | - Amy Leber
- Nationwide Children’s Hospital, Columbus, Ohio, USA
| | | | | | | | - Judy Daly
- Primary Children’s Hospital, Salt Lake City, Utah, USA
| | - Rebecca Barr
- Primary Children’s Hospital, Salt Lake City, Utah, USA
| | | | | | | |
Collapse
|
2
|
Browning S, Manning L, Metcalf S, Paterson DL, Robinson JO, Clark B, Davis JS. Characteristics and outcomes of culture-negative prosthetic joint infections from the Prosthetic Joint Infection in Australia and New Zealand Observational (PIANO) cohort study. J Bone Jt Infect 2022; 7:203-211. [DOI: 10.5194/jbji-7-203-2022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2022] [Accepted: 08/31/2022] [Indexed: 11/11/2022] Open
Abstract
Abstract. Introduction:
Culture-negative (CN) prosthetic joint infections (PJIs) account for
approximately 10 % of all PJIs and present significant challenges for
clinicians. We aimed to explore the significance of CN PJIs within a large
prospective cohort study, comparing their characteristics and outcomes with
culture-positive (CP) cases.
Methods:
The Prosthetic joint Infection in Australia and New Zealand Observational
(PIANO) study is a prospective, multicentre observational cohort study
that was conducted at 27 hospitals between 2014 and 2017. We compared baseline
characteristics and outcomes of all patients with CN PJI from the PIANO
cohort with those of CP cases. We report on PJI diagnostic criteria in the CN cohort
and apply internationally recognized PJI diagnostic guidelines to determine
optimal CN PJI detection methods.
Results:
Of the 650 patients with 24-month outcome data available, 55 (8.5 %) were
CN and 595 were CP. Compared with the CP cohort, CN patients were more
likely to be female (32 (58.2 %) vs. 245 (41.2 %); p = 0.016), involve
the shoulder joint (5 (9.1 %) vs. 16 (2.7 %); p = 0.026), and have a
lower mean C-reactive protein (142 mg L−1 vs. 187 mg L−1; p = 0.016). Overall,
outcomes were superior in CN patients, with culture negativity an
independent predictor of treatment success at 24 months (adjusted odds ratio, aOR, of 3.78 and 95 %CI of
1.65–8.67). Suboptimal diagnostic sampling was common in both cohorts,
with CN PJI case detection enhanced using the Infectious Diseases Society of
America PJI diagnostic guidelines.
Conclusions:
Current PJI diagnostic guidelines vary substantially in their ability to
detect CN PJI, with comprehensive diagnostic sampling necessary to achieve
diagnostic certainty. Definitive surgical management strategies should be
determined by careful assessment of infection type, rather than by culture
status alone.
Collapse
|
3
|
Comini S, Scutera S, Sparti R, Banche G, Coppola B, Bertea CM, Bianco G, Gatti N, Cuffini AM, Palmero P, Allizond V. Combination of Poly(ε-Caprolactone) Biomaterials and Essential Oils to Achieve Anti-Bacterial and Osteo-Proliferative Properties for 3D-Scaffolds in Regenerative Medicine. Pharmaceutics 2022; 14:pharmaceutics14091873. [PMID: 36145620 PMCID: PMC9506294 DOI: 10.3390/pharmaceutics14091873] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Revised: 08/26/2022] [Accepted: 09/01/2022] [Indexed: 12/13/2022] Open
Abstract
Biomedical implants, an essential part of the medical treatments, still suffer from bacterial infections that hamper patients’ recovery and lives. Antibiotics are widely used to cure those infections but brought antibiotic resistance. Essential oils (EOs) demonstrate excellent antimicrobial activity and low resistance development risk. However, EO application in medicine is still quite scarce and almost no research work considers its use in combination with bioresorbable biomaterials, such as the poly(ε-caprolactone) (PCL) polymer. This work aimed to combine the antibacterial properties of EOs and their components, particularly eugenol and cinnamon oil, against Staphylococcus aureus, S. epidermidis and Escherichia coli, with those of PCL for medical applications in which good tissue regeneration and antimicrobial effects are required. The PCL porous scaffolds, added with increasing (from 30% to 50%) concentrations of eugenol and cinnamon oil, were characterized by square-shaped macropores. Saos-2 cells’ cell viability/proliferation was hampered by 40 and 50% EO-enriched PCL, whereas no cytotoxic effect was recorded for both 30% EO-added PCL and pure-PCL. The antibacterial tests revealed the presence of a small inhibition halo around the 30% eugenol and cinnamon oil-functionalized PCL scaffolds only for staphylococci, whereas a significant decrease on both adherent and planktonic bacteria was recorded for all the three microorganisms, thus proving that, even if the EOs are only in part released by the EO-added PCL scaffolds, an anti-adhesive feature is anyway achieved. The scaffold will have the ability to support new tissue formation and simultaneously will be able to prevent post-surgical infection. This research shows the great potential in the use of EOs or their single components, at low concentrations, for biomaterial functionalization with enhanced anti-bacterial and biointegration properties.
Collapse
Affiliation(s)
- Sara Comini
- Department of Public Health and Pediatrics, University of Torino, Via Santena 9, 10126 Turin, Italy
| | - Sara Scutera
- Department of Public Health and Pediatrics, University of Torino, Via Santena 9, 10126 Turin, Italy
| | - Rosaria Sparti
- Department of Public Health and Pediatrics, University of Torino, Via Santena 9, 10126 Turin, Italy
| | - Giuliana Banche
- Department of Public Health and Pediatrics, University of Torino, Via Santena 9, 10126 Turin, Italy
- Correspondence: (G.B.); (A.M.C.); Tel.: +39-011-670-5627 (G.B.); +39-011-670-5638 (A.M.C.)
| | - Bartolomeo Coppola
- Department of Applied Science and Technology, Politecnico di Torino, Corso Duca degli Abruzzi, 24, 10129 Turin, Italy
| | - Cinzia Margherita Bertea
- Department of Life Sciences and Systems Biology, University of Torino, Via Quarello 15/A, 10135 Turin, Italy
| | - Gabriele Bianco
- Microbiology and Virology Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Corso Bramante 88/90, 10126 Turin, Italy
| | - Noemi Gatti
- Department of Life Sciences and Systems Biology, University of Torino, Via Quarello 15/A, 10135 Turin, Italy
| | - Anna Maria Cuffini
- Department of Public Health and Pediatrics, University of Torino, Via Santena 9, 10126 Turin, Italy
- Correspondence: (G.B.); (A.M.C.); Tel.: +39-011-670-5627 (G.B.); +39-011-670-5638 (A.M.C.)
| | - Paola Palmero
- Department of Applied Science and Technology, Politecnico di Torino, Corso Duca degli Abruzzi, 24, 10129 Turin, Italy
| | - Valeria Allizond
- Department of Public Health and Pediatrics, University of Torino, Via Santena 9, 10126 Turin, Italy
| |
Collapse
|
4
|
Current Knowledge on Biomaterials for Orthopedic Applications Modified to Reduce Bacterial Adhesive Ability. Antibiotics (Basel) 2022; 11:antibiotics11040529. [PMID: 35453280 PMCID: PMC9024841 DOI: 10.3390/antibiotics11040529] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Revised: 04/08/2022] [Accepted: 04/11/2022] [Indexed: 02/01/2023] Open
Abstract
A significant challenge in orthopedics is the design of biomaterial devices that are able to perform biological functions by substituting or repairing various tissues and controlling bone repair when required. This review presents an overview of the current state of our recent research into biomaterial modifications to reduce bacterial adhesive ability, compared with previous reviews and excellent research papers, but it is not intended to be exhaustive. In particular, we investigated biomaterials for replacement, such as metallic materials (titanium and titanium alloys) and polymers (ultra-high-molecular-weight polyethylene), and biomaterials for regeneration, such as poly(ε-caprolactone) and calcium phosphates as composites. Biomaterials have been designed, developed, and characterized to define surface/bulk features; they have also been subjected to bacterial adhesion assays to verify their potential capability to counteract infections. The addition of metal ions (e.g., silver), natural antimicrobial compounds (e.g., essential oils), or antioxidant agents (e.g., vitamin E) to different biomaterials conferred strong antibacterial properties and anti-adhesive features, improving their capability to counteract prosthetic joint infections and biofilm formation, which are important issues in orthopedic surgery. The complexity of biological materials is still far from being reached by materials science through the development of sophisticated biomaterials. However, close interdisciplinary work by materials scientists, engineers, microbiologists, chemists, physicists, and orthopedic surgeons is indeed necessary to modify the structures of biomaterials in order to achieve implant integration and tissue regeneration while avoiding microbial contamination.
Collapse
|
5
|
Comini S, Sparti R, Coppola B, Mohammadi M, Scutera S, Menotti F, Banche G, Cuffini AM, Palmero P, Allizond V. Novel Silver-Functionalized Poly(ε-Caprolactone)/Biphasic Calcium Phosphate Scaffolds Designed to Counteract Post-Surgical Infections in Orthopedic Applications. Int J Mol Sci 2021; 22:10176. [PMID: 34576339 PMCID: PMC8471985 DOI: 10.3390/ijms221810176] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Revised: 09/16/2021] [Accepted: 09/17/2021] [Indexed: 12/17/2022] Open
Abstract
In this study, we designed and developed novel poly(ε-caprolactone) (PCL)-based biomaterials, for use as bone scaffolds, through modification with both biphasic calcium phosphate (BCP), to impart bioactive/bioresorbable properties, and with silver nitrate, to provide antibacterial protection against Staphylococcus aureus, a microorganism involved in prosthetic joint infections (PJIs). Field emission scanning electron microscopy (FESEM) showed that the samples were characterized by square-shaped macropores, and energy dispersive X-ray spectroscopy analysis confirmed the presence of PCL and BCP phases, while inductively coupled plasma-mass spectrometry (ICP-MS) established the release of Ag+ in the medium (~0.15-0.8 wt% of initial Ag content). Adhesion assays revealed a significant (p < 0.0001) reduction in both adherent and planktonic staphylococci on the Ag-functionalized biomaterials, and the presence of an inhibition halo confirmed Ag release from enriched samples. To assess the potential outcome in promoting bone integration, preliminary tests on sarcoma osteogenic-2 (Saos-2) cells indicated PCL and BCP/PCL biocompatibility, but a reduction in viability was observed for Ag-added biomaterials. Due to their combined biodegrading and antimicrobial properties, the silver-enriched BCP/PCL-based scaffolds showed good potential for engineering of bone tissue and for reducing PJIs as a microbial anti-adhesive tool used in the delivery of targeted antimicrobial molecules, even if the amount of silver needs to be tuned to improve osteointegration.
Collapse
Affiliation(s)
- Sara Comini
- Bacteriology and Mycology Laboratory, Department of Public Health and Pediatrics, University of Torino, Via Santena 9, 10126 Turin, Italy; (S.C.); (F.M.); (A.M.C.); (V.A.)
| | - Rosaria Sparti
- Immunology Laboratory, Department of Public Health and Pediatrics, University of Torino, Via Santena 9, 10126 Turin, Italy; (R.S.); (S.S.)
| | - Bartolomeo Coppola
- INSTM R.U. Lince Laboratory, Department of Applied Science and Technology, Politecnico di Torino, Corso Duca degli Abruzzi, 24, 10129 Turin, Italy; (B.C.); (M.M.); (P.P.)
| | - Mehdi Mohammadi
- INSTM R.U. Lince Laboratory, Department of Applied Science and Technology, Politecnico di Torino, Corso Duca degli Abruzzi, 24, 10129 Turin, Italy; (B.C.); (M.M.); (P.P.)
| | - Sara Scutera
- Immunology Laboratory, Department of Public Health and Pediatrics, University of Torino, Via Santena 9, 10126 Turin, Italy; (R.S.); (S.S.)
| | - Francesca Menotti
- Bacteriology and Mycology Laboratory, Department of Public Health and Pediatrics, University of Torino, Via Santena 9, 10126 Turin, Italy; (S.C.); (F.M.); (A.M.C.); (V.A.)
| | - Giuliana Banche
- Bacteriology and Mycology Laboratory, Department of Public Health and Pediatrics, University of Torino, Via Santena 9, 10126 Turin, Italy; (S.C.); (F.M.); (A.M.C.); (V.A.)
| | - Anna Maria Cuffini
- Bacteriology and Mycology Laboratory, Department of Public Health and Pediatrics, University of Torino, Via Santena 9, 10126 Turin, Italy; (S.C.); (F.M.); (A.M.C.); (V.A.)
| | - Paola Palmero
- INSTM R.U. Lince Laboratory, Department of Applied Science and Technology, Politecnico di Torino, Corso Duca degli Abruzzi, 24, 10129 Turin, Italy; (B.C.); (M.M.); (P.P.)
| | - Valeria Allizond
- Bacteriology and Mycology Laboratory, Department of Public Health and Pediatrics, University of Torino, Via Santena 9, 10126 Turin, Italy; (S.C.); (F.M.); (A.M.C.); (V.A.)
| |
Collapse
|